| Budget Amount *help |
¥104,910,000 (Direct Cost: ¥80,700,000、Indirect Cost: ¥24,210,000)
Fiscal Year 2021: ¥21,450,000 (Direct Cost: ¥16,500,000、Indirect Cost: ¥4,950,000)
Fiscal Year 2020: ¥21,450,000 (Direct Cost: ¥16,500,000、Indirect Cost: ¥4,950,000)
Fiscal Year 2019: ¥21,450,000 (Direct Cost: ¥16,500,000、Indirect Cost: ¥4,950,000)
Fiscal Year 2018: ¥21,450,000 (Direct Cost: ¥16,500,000、Indirect Cost: ¥4,950,000)
Fiscal Year 2017: ¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
|
|---|
| Outline of Final Research Achievements |
Biosynthetic pathway of antifungals 5aTHQs and antibiotics STAMs, which are produced by combined-culture of Streptomyces sp. HEK616 and Tsukamurella pulmonis TP-B0596, were revealed. Moreover, antifungals 5aTHQs were shown to form aggregates that show enhanced membrane affinity and biological activity. Additionally, inspired by an extremely rare natural products yaku’amids, novel highly sensitive labeling reagents that would be powerful tools for scarce chemical communication molecules (natural products) were designed and synthesized, enabling us the development of highly sensitive advanced Merfey’s method. Furthermore, an innovative anticancer prodrug CMG (curcumin monoglucuronide) was developed, demonstrating not only its potent antitumor activity in oxaliplatin-resistant colon cancer but also its multiple sclerosis modulator with altered gut microbiota.
|
